Valuation: Verastem, Inc.

Market Cap 543M 477M 444M 407M 765M 52.3B 777M 5.27B 2.06B 25.71B 2.04B 1.99B 88.9B P/E 2026 *
-3.9x
P/E 2027 * -5.51x
Enterprise Value 378M 332M 309M 283M 532M 36.41B 541M 3.67B 1.43B 17.9B 1.42B 1.39B 61.89B EV / Sales 2026 *
3.71x
EV / Sales 2027 * 1.87x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-2.18%
1 week+0.50%
Current month+58.64%
1 month+57.40%
3 months+2.54%
6 months-2.88%
Current year-21.50%
1 week 5.7
Extreme 5.7
6.3
1 month 3.43
Extreme 3.43
6.3
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/6/26 Sell

Chief Executive Officer

-20,871 0.0339%
22/6/26 Sell

Chief Financial Officer

-4,089 0.0066%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-2.18%+0.50%+14.56%-37.27% 543M
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+6.97%+62.83%+67.97% 56.67B
-2.48%-1.90%-21.67%-16.15% 23.28B
-0.14%-1.15%+3.43%+423.33% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%+0.51%+25.02%-30.27% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
-0.58%-0.95%+23.67%+178.48% 13.99B
Average -1.09%+1.14%+39.03%+154.08% 24.25B
Weighted average by Cap. -0.82%+1.48%+42.57%+137.91%

Financials

2026 *2027 *
Net sales 102M 89.47M 83.21M 76.35M 143M 9.81B 146M 988M 386M 4.82B 382M 374M 16.68B 178M 157M 146M 134M 251M 17.18B 255M 1.73B 676M 8.44B 670M 655M 29.19B
Net income -166M -145M -135M -124M -233M -15.94B -237M -1.61B -627M -7.84B -621M -608M -27.1B -142M -125M -116M -106M -200M -13.68B -203M -1.38B -538M -6.73B -533M -522M -23.26B
Net Debt -165M -145M -135M -124M -232M -15.89B -236M -1.6B -625M -7.81B -619M -606M -27.01B -210M -184M -171M -157M -295M -20.18B -300M -2.03B -794M -9.92B -787M -770M -34.31B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
25/07/26 USD 6.055 -2.02% 804,274
23/07/26 USD 6.180 +4.92% 2,193,680
22/07/26 USD 5.890 -1.83% 1,342,979
21/07/26 USD 6.000 +4.35% 2,532,260
20/07/26 USD 5.750 -4.64% 2,532,687
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.180USD
Average target price
15.00USD
Spread / Average Target
+142.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock